Major Investor Discloses 20.1% Potential Stake from Convertible Notes and Warrants
CELU sits 21% above its 52-week low of $1.01.
Summary
An amendment to a Schedule 13D reveals that the Philip & Daniele Barach Family Trust now beneficially owns 20.1% of Celularity Inc.'s Class A Common Stock, primarily due to convertible notes and warrants becoming exercisable within 60 days.
Key Events · Ownership and Investor Activity · CELU
-
Increased Beneficial Ownership
The Philip & Daniele Barach Family Trust and related individuals now beneficially own 7,558,665 shares, representing 20.1% of the Class A Common Stock.
-
Warrants Become Exercisable
The increase in reported beneficial ownership is primarily due to 4,546,617 shares from warrants becoming exercisable within 60 days, starting June 19, 2026.
-
Source of Funds
The beneficial ownership stems from a $10 million financing package in December 2025, consisting of senior secured and convertible promissory notes, along with associated warrants.
Analysis · CELU · Life Sciences
This Schedule 13D/A updates the beneficial ownership of the Philip & Daniele Barach Family Trust and related individuals to 20.1% of Celularity Inc.'s Class A Common Stock. This amendment follows the original Schedule 13D filed on April 3, 2026. The significant increase in reported ownership is primarily due to 4,546,617 shares from warrants, issued as part of a $10 million financing in December 2025, now becoming exercisable within 60 days. While the original financing provided critical capital to the company, the impending exercisability of these derivatives creates a notable overhang and potential for substantial dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.2M. The 52-week trading range was $1.01 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.